Free Trial

Mitsubishi UFJ Asset Management Co. Ltd. Buys 92,634 Shares of Corteva, Inc. $CTVA

Corteva logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Mitsubishi UFJ Asset Management increased its Corteva stake by 6.8% in Q4, buying 92,634 shares to own 1,448,541 shares (about 0.21%) valued at roughly $98.15 million.
  • Corteva beat Q1 expectations with $1.50 EPS (vs. $1.18 est.) and $4.91B revenue (vs. $4.64B est.), reaffirmed FY2026 guidance of $3.45–$3.70 EPS and announced a $0.18 quarterly dividend (0.9% yield).
  • Analyst views lifted price targets (e.g., Jefferies $97, UBS $90, Citigroup $85) and MarketBeat shows a "Moderate Buy" consensus with a $86.95 target, while the stock recently traded near $79.14 and was down ~3.2%.
  • MarketBeat previews the top five stocks to own by June 1st.

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 6.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,448,541 shares of the company's stock after purchasing an additional 92,634 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.21% of Corteva worth $98,153,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of CTVA. Activest Wealth Management lifted its position in Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company's stock valued at $25,000 after purchasing an additional 200 shares during the last quarter. JPL Wealth Management LLC bought a new stake in Corteva during the third quarter valued at approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Corteva during the third quarter valued at approximately $29,000. Jackson Grant Investment Advisers Inc. lifted its position in Corteva by 90.6% during the third quarter. Jackson Grant Investment Advisers Inc. now owns 448 shares of the company's stock valued at $30,000 after purchasing an additional 213 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in Corteva during the third quarter valued at approximately $33,000. 81.54% of the stock is currently owned by institutional investors.

Corteva Trading Down 3.2%

Shares of CTVA opened at $79.14 on Friday. The firm has a market cap of $53.13 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 2.81 and a beta of 0.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.47. Corteva, Inc. has a fifty-two week low of $60.53 and a fifty-two week high of $85.63. The firm has a 50 day moving average price of $80.68 and a 200-day moving average price of $72.61.

Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, topping analysts' consensus estimates of $1.18 by $0.32. The firm had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business's quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, equities research analysts forecast that Corteva, Inc. will post 3.62 earnings per share for the current year.

Corteva Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Monday, June 1st will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Monday, June 1st. Corteva's payout ratio is presently 45.57%.

Insider Activity at Corteva

In related news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction on Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the transaction, the insider directly owned 8,090 shares of the company's stock, valued at $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.15% of the stock is currently owned by insiders.

Key Corteva News

Here are the key news stories impacting Corteva this week:

  • Positive Sentiment: Q1 results were strong — Corteva beat expectations, reaffirmed its 2026 outlook and said it remains on track for the planned 4Q-2026 separation, underpinning earnings visibility and growth prospects. Corteva Delivers Strong 1Q 2026 (Finanznachrichten)
  • Positive Sentiment: Jefferies raised its price target to $97 (about ~21.6% upside vs. current levels), signaling bullish analyst conviction that could support further upside if investors follow. Jefferies raises PT to $97 (MarketScreener)
  • Positive Sentiment: UBS lifted its price target to $90 (though it kept a "neutral" rating), which increases implied upside and may support buying interest among investors focused on valuation. UBS raises PT to $90 (Benzinga)
  • Positive Sentiment: Citigroup raised its target to $85 while maintaining a "neutral" rating — another upward revision that suggests analysts are incrementally more constructive on Corteva's outlook. Citigroup raises PT to $85 (TickerReport)
  • Neutral Sentiment: Corteva management will speak at the BMO Global Farm to Market conference (May 14). Investor presentations and Q&A could provide incremental color but are routine events. Corteva to Participate in BMO Conference (PRNewswire)
  • Neutral Sentiment: Full Q1 earnings call transcript and presentation are available for deeper detail on margins, guidance and separation timing — useful for active investors but not new headline news. Q1 Earnings Transcript (Yahoo) Earnings Call Transcript (Seeking Alpha)
  • Negative Sentiment: BNP Paribas raised its target only to $77, which implies downside versus current levels and signals at least one analyst thinks upside is limited — a potential headwind for sentiment. BNP Paribas raises PT to $77 (MarketScreener)

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Oppenheimer lifted their target price on shares of Corteva from $86.00 to $89.00 and gave the company an "outperform" rating in a research report on Wednesday, April 22nd. Royal Bank Of Canada boosted their price objective on shares of Corteva from $89.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, April 24th. JPMorgan Chase & Co. lowered shares of Corteva from an "overweight" rating to a "neutral" rating and boosted their price objective for the stock from $75.00 to $77.00 in a report on Thursday, February 5th. Citigroup boosted their price objective on shares of Corteva from $83.00 to $85.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, Rothschild & Co Redburn boosted their price objective on shares of Corteva from $80.00 to $90.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Corteva has a consensus rating of "Moderate Buy" and a consensus price target of $86.95.

View Our Latest Stock Analysis on CTVA

Corteva Profile

(Free Report)

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

Featured Stories

Institutional Ownership by Quarter for Corteva (NYSE:CTVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Corteva Right Now?

Before you consider Corteva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.

While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines